Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: A consensus proposal

Peter Valent, Cem Akin, Michel Arock, Knut Brockow, Joseph H. Butterfield, Melody C. Carter, Mariana Castells, Luis Escribano, Karin Hartmann, Philip Lieberman, Boguslaw Nedoszytko, Alberto Orfao, Lawrence B. Schwartz, Karl Sotlar, Wolfgang R. Sperr, Massimo Triggiani, Rudolf Valenta, Hans Peter Horny, Dean D. Metcalfe

Research output: Contribution to journalArticle

298 Citations (Scopus)

Abstract

Activation of tissue mast cells (MCs) and their abnormal growth and accumulation in various organs are typically found in primary MC disorders also referred to as mastocytosis. However, increasing numbers of patients are now being informed that their clinical findings are due to MC activation (MCA) that is neither associated with mastocytosis nor with a defined allergic or inflammatory reaction. In other patients with MCA, MCs appear to be clonal cells, but criteria for diagnosing mastocytosis are not met. A working conference was organized in 2010 with the aim to define criteria for diagnosing MCA and related disorders, and to propose a global unifying classification of all MC disorders and pathologic MC reactions. This classification includes three types of 'MCA syndromes' (MCASs), namely primary MCAS, secondary MCAS and idiopathic MCAS. MCA is now defined by robust and generally applicable criteria, including (1) typical clinical symptoms, (2) a substantial transient increase in serum total tryptase level or an increase in other MC-derived mediators, such as histamine or prostaglandin D 2 , or their urinary metabolites, and (3) a response of clinical symptoms to agents that attenuate the production or activities of MC mediators. These criteria should assist in the identification and diagnosis of patients with MCAS, and in avoiding misdiagnoses or overinterpretation of clinical symptoms in daily practice. Moreover, the MCAS concept should stimulate research in order to identify and exploit new molecular mechanisms and therapeutic targets.

Original languageEnglish (US)
Pages (from-to)215-225
Number of pages11
JournalInternational Archives of Allergy and Immunology
Volume157
Issue number3
DOIs
StatePublished - Feb 2012

Fingerprint

Mast Cells
Mastocytosis
Prostaglandins D
Tryptases
Diagnostic Errors
Histamine
Growth
Serum
Research

Keywords

  • Allergy
  • Anaphylaxis
  • Mast cell activation syndrome
  • Mast cells
  • Tryptase

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes : A consensus proposal. / Valent, Peter; Akin, Cem; Arock, Michel; Brockow, Knut; Butterfield, Joseph H.; Carter, Melody C.; Castells, Mariana; Escribano, Luis; Hartmann, Karin; Lieberman, Philip; Nedoszytko, Boguslaw; Orfao, Alberto; Schwartz, Lawrence B.; Sotlar, Karl; Sperr, Wolfgang R.; Triggiani, Massimo; Valenta, Rudolf; Horny, Hans Peter; Metcalfe, Dean D.

In: International Archives of Allergy and Immunology, Vol. 157, No. 3, 02.2012, p. 215-225.

Research output: Contribution to journalArticle

Valent, P, Akin, C, Arock, M, Brockow, K, Butterfield, JH, Carter, MC, Castells, M, Escribano, L, Hartmann, K, Lieberman, P, Nedoszytko, B, Orfao, A, Schwartz, LB, Sotlar, K, Sperr, WR, Triggiani, M, Valenta, R, Horny, HP & Metcalfe, DD 2012, 'Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: A consensus proposal', International Archives of Allergy and Immunology, vol. 157, no. 3, pp. 215-225. https://doi.org/10.1159/000328760
Valent, Peter ; Akin, Cem ; Arock, Michel ; Brockow, Knut ; Butterfield, Joseph H. ; Carter, Melody C. ; Castells, Mariana ; Escribano, Luis ; Hartmann, Karin ; Lieberman, Philip ; Nedoszytko, Boguslaw ; Orfao, Alberto ; Schwartz, Lawrence B. ; Sotlar, Karl ; Sperr, Wolfgang R. ; Triggiani, Massimo ; Valenta, Rudolf ; Horny, Hans Peter ; Metcalfe, Dean D. / Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes : A consensus proposal. In: International Archives of Allergy and Immunology. 2012 ; Vol. 157, No. 3. pp. 215-225.
@article{99a15f52ce4d469eb02a4760dd34ba44,
title = "Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: A consensus proposal",
abstract = "Activation of tissue mast cells (MCs) and their abnormal growth and accumulation in various organs are typically found in primary MC disorders also referred to as mastocytosis. However, increasing numbers of patients are now being informed that their clinical findings are due to MC activation (MCA) that is neither associated with mastocytosis nor with a defined allergic or inflammatory reaction. In other patients with MCA, MCs appear to be clonal cells, but criteria for diagnosing mastocytosis are not met. A working conference was organized in 2010 with the aim to define criteria for diagnosing MCA and related disorders, and to propose a global unifying classification of all MC disorders and pathologic MC reactions. This classification includes three types of 'MCA syndromes' (MCASs), namely primary MCAS, secondary MCAS and idiopathic MCAS. MCA is now defined by robust and generally applicable criteria, including (1) typical clinical symptoms, (2) a substantial transient increase in serum total tryptase level or an increase in other MC-derived mediators, such as histamine or prostaglandin D 2 , or their urinary metabolites, and (3) a response of clinical symptoms to agents that attenuate the production or activities of MC mediators. These criteria should assist in the identification and diagnosis of patients with MCAS, and in avoiding misdiagnoses or overinterpretation of clinical symptoms in daily practice. Moreover, the MCAS concept should stimulate research in order to identify and exploit new molecular mechanisms and therapeutic targets.",
keywords = "Allergy, Anaphylaxis, Mast cell activation syndrome, Mast cells, Tryptase",
author = "Peter Valent and Cem Akin and Michel Arock and Knut Brockow and Butterfield, {Joseph H.} and Carter, {Melody C.} and Mariana Castells and Luis Escribano and Karin Hartmann and Philip Lieberman and Boguslaw Nedoszytko and Alberto Orfao and Schwartz, {Lawrence B.} and Karl Sotlar and Sperr, {Wolfgang R.} and Massimo Triggiani and Rudolf Valenta and Horny, {Hans Peter} and Metcalfe, {Dean D.}",
year = "2012",
month = "2",
doi = "10.1159/000328760",
language = "English (US)",
volume = "157",
pages = "215--225",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes

T2 - A consensus proposal

AU - Valent, Peter

AU - Akin, Cem

AU - Arock, Michel

AU - Brockow, Knut

AU - Butterfield, Joseph H.

AU - Carter, Melody C.

AU - Castells, Mariana

AU - Escribano, Luis

AU - Hartmann, Karin

AU - Lieberman, Philip

AU - Nedoszytko, Boguslaw

AU - Orfao, Alberto

AU - Schwartz, Lawrence B.

AU - Sotlar, Karl

AU - Sperr, Wolfgang R.

AU - Triggiani, Massimo

AU - Valenta, Rudolf

AU - Horny, Hans Peter

AU - Metcalfe, Dean D.

PY - 2012/2

Y1 - 2012/2

N2 - Activation of tissue mast cells (MCs) and their abnormal growth and accumulation in various organs are typically found in primary MC disorders also referred to as mastocytosis. However, increasing numbers of patients are now being informed that their clinical findings are due to MC activation (MCA) that is neither associated with mastocytosis nor with a defined allergic or inflammatory reaction. In other patients with MCA, MCs appear to be clonal cells, but criteria for diagnosing mastocytosis are not met. A working conference was organized in 2010 with the aim to define criteria for diagnosing MCA and related disorders, and to propose a global unifying classification of all MC disorders and pathologic MC reactions. This classification includes three types of 'MCA syndromes' (MCASs), namely primary MCAS, secondary MCAS and idiopathic MCAS. MCA is now defined by robust and generally applicable criteria, including (1) typical clinical symptoms, (2) a substantial transient increase in serum total tryptase level or an increase in other MC-derived mediators, such as histamine or prostaglandin D 2 , or their urinary metabolites, and (3) a response of clinical symptoms to agents that attenuate the production or activities of MC mediators. These criteria should assist in the identification and diagnosis of patients with MCAS, and in avoiding misdiagnoses or overinterpretation of clinical symptoms in daily practice. Moreover, the MCAS concept should stimulate research in order to identify and exploit new molecular mechanisms and therapeutic targets.

AB - Activation of tissue mast cells (MCs) and their abnormal growth and accumulation in various organs are typically found in primary MC disorders also referred to as mastocytosis. However, increasing numbers of patients are now being informed that their clinical findings are due to MC activation (MCA) that is neither associated with mastocytosis nor with a defined allergic or inflammatory reaction. In other patients with MCA, MCs appear to be clonal cells, but criteria for diagnosing mastocytosis are not met. A working conference was organized in 2010 with the aim to define criteria for diagnosing MCA and related disorders, and to propose a global unifying classification of all MC disorders and pathologic MC reactions. This classification includes three types of 'MCA syndromes' (MCASs), namely primary MCAS, secondary MCAS and idiopathic MCAS. MCA is now defined by robust and generally applicable criteria, including (1) typical clinical symptoms, (2) a substantial transient increase in serum total tryptase level or an increase in other MC-derived mediators, such as histamine or prostaglandin D 2 , or their urinary metabolites, and (3) a response of clinical symptoms to agents that attenuate the production or activities of MC mediators. These criteria should assist in the identification and diagnosis of patients with MCAS, and in avoiding misdiagnoses or overinterpretation of clinical symptoms in daily practice. Moreover, the MCAS concept should stimulate research in order to identify and exploit new molecular mechanisms and therapeutic targets.

KW - Allergy

KW - Anaphylaxis

KW - Mast cell activation syndrome

KW - Mast cells

KW - Tryptase

UR - http://www.scopus.com/inward/record.url?scp=79959598455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959598455&partnerID=8YFLogxK

U2 - 10.1159/000328760

DO - 10.1159/000328760

M3 - Article

C2 - 22041891

AN - SCOPUS:79959598455

VL - 157

SP - 215

EP - 225

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 3

ER -